Active Study Portfolio

A Phase I/II Trial of Concurrent Chemohormonal Therapy Using Enzalutamide (MDV-3100) and Cabazitaxel in Patients with Metastatic Castration Resistant Prostate Cancer (NCT02522715)

ARN-509 + Abiraterone acetate + Leuprolide with Stereotactic, Ultra-Hypofractionated Radiation (AASUR) in Very High-Risk Prostate Cancer: A Single Arm, Phase II Study (NCT02772588)

A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients with Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (NCT03012321)

IRONMAN: International Registry for Men with Advanced Prostate Cancer (NCT03151629)

PRODIGY: Observational study to describe effectiveness of olaparib in subjects with metastatic castration-resistant prostate cancer who have failed prior treatment with a new hormonal agent and carry selected homologous recombination repair gene mutations (An IRONMAN Registry Substudy)

EMPRO: Engaging Men in Patient Reported Outcomes (An IRONMAN Registry Substudy)

CUETIP: Clinical Utility of an AI-Enabled PSMA-Targeted Imaging Biomarker in Prostate Cancer (An IRONMAN Registry Substudy)

BIOGUARD: BIOmarker landscape in GU cancers: Assessment in the Real-worlD (An IRONMAN Registry Substudy)

IRONSeq: Characterizing the whole genome landscape of the IRONMAN Registry (An IRONMAN Registry Substudy)

Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (NCT03574571)

Metacure: Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma (NCT03436654)

A Phase II Study of Carboplatin, Cabazitaxel and Abiraterone in High Volume Metastatic Castration Sensitive Prostate Cancer (CASCARA) (NCT03934840)

A Single-arm, Phase 2 Study to Evaluate the Safety and Efficacy of IMMU-132 in Patients with Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone (NCT03725761)

A Phase Ib/II Study of Intermittent Talazoparib Plus Temozolomide in Subjects with Metastatic Castration Resistant Prostate Cancer and No Mutations in DNA Damage Repair (NCT04019327)

An open-label Phase I/IIa study to evaluate the safety and efficacy of CCS1477 as monotherapy and in combination in patients with advanced solid/metastatic tumours (NCT03568656)

Single Arm Phase II Study of Abiraterone + Atezolizumab + Lupron and Stereotactic Body Radiotherapy (SBRT) to the Prostate in Men with Newly Diagnosed Hormone-sensitive Metastatic Prostate Cancer (NCT04262154)

A Phase 2 Multicohort Study of Nivolumab in Combination with Docetaxel and Androgen Deprivation Therapy in Metastatic Hormone Sensitive Prostate Cancer Patients with DNA Damage Repair Defects or Inflamed Tumors (NCT04126070)

PROMISE: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness (NCT04995198)

An open-label Phase I/IIa study to evaluate the safety and efficacy of CCS1477 as monotherapy in patients with advanced haematological malignancies (NCT04068597)

DASL-HiCaP: Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (ANZUP1801). A randomised phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high risk, clinically localised prostate cancer (NCT04136353)

Neoadjuvant darolutamide and abemaciclib in high-risk prostate cancer (NCT05617885)

A Phase 1b/2 Study Evaluating the Activity of Tinengotinib (TT–00420) in Combination with Androgen Receptor Signaling Inhibitors (ARSIs) in Patients with Metastatic Castration Resistant Prostate Cancer (NCT06457919)